HC Wainwright & Co. Reiterates Buy on Syros Pharmaceuticals, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Syros Pharmaceuticals (NASDAQ:SYRS) and maintained a price target of $15.
May 15, 2024 | 10:56 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Syros Pharmaceuticals and maintained a price target of $15, indicating strong confidence in the company's future performance.
The reiteration of a Buy rating and a maintained price target of $15 by HC Wainwright & Co. suggests strong confidence in Syros Pharmaceuticals' future performance. This is likely to positively impact the stock price in the short term as investors may view this as a bullish signal.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100